Providers Still See Drawbacks To Opioid Education Mandates

The US Food & Drug Administration is already planning additional meetings to consider ways to make mandatory prescriber education for opioid providers less burdensome and easier to implement, Center for Drug Evaluation and Research Director Patrizia Cavazzoni indicated during opening remarks at an FDA/Duke-Margolis meeting last month on potential changes to the opioid Risk Evaluation & Mitigation Strategy.